RAPID-PsA: burden of PsA on productivity in the workplace and within the home at study baseline (RS population, observed cases)
| Placebo | CZP 200 mg Q2W | CZP 400 mg Q4W | All patients | |||||
|---|---|---|---|---|---|---|---|---|
| Mean | Median | Mean | Median | Mean | Median | Mean | Median | |
| Productivity at the workplace over previous month (employed patients only) | n=77 | n=83 | n=83 | n=243 | ||||
| Work days missed due to arthritis | 2.6 | 0.0 | 2.0 | 0.0 | 1.6 | 0.0 | 2.0 | 0.0 |
| Days with work productivity reduced by ≥50% due to arthritis* | 3.8 | 0.0 | 5.2 | 0.0 | 5.1 | 0.0 | 4.7 | 0.0 |
| Rate of arthritis interference with work productivity† | 4.2 | 5.0 | 4.4 | 5.0 | 3.8 | 4.0 | 4.1 | 5.0 |
| Productivity at home and daily activities over previous month | n=136 | n=138 | n=135 | n=409 | ||||
| Days with no household work due to arthritis | 5.6 | 1.5 | 5.9 | 0.0 | 5.5 | 2.0 | 5.7 | 2.0 |
| Days with household work productivity reduced by ≥50% due to arthritis* | 8.6 | 5.0 | 7.1 | 4.0 | 7.1 | 5.0 | 7.6 | 5.0 |
| Days missed of family, social or leisure activities due to arthritis | 3.7 | 0.0 | 4.1 | 0.0 | 3.3 | 0.0 | 3.7 | 0.0 |
| Days with outside help hired due to arthritis | 2.2 | 0.0 | 2.5 | 0.0 | 2.7 | 0.0 | 2.4 | 0.0 |
| Rate of arthritis interference with household work productivity† | 4.9 | 5.0 | 5.2 | 5.0 | 4.9 | 5.0 | 5.0 | 5.0 |
*Does not include days counted in the previous question, ‘Work days missed due to arthritis’.
†0–10 scale, where 0=no interference, 10=complete interference.
CZP, certolizumab pegol; PsA, psoriatic arthritis; Q2W, every 2 weeks; Q4W, every 4 weeks; RS, randomised set.